183 related articles for article (PubMed ID: 29278339)
21. Early arthritis clinic is effective for rheumatoid and psoriatic arthritides.
Nisar MK
Rheumatol Int; 2019 Apr; 39(4):657-662. PubMed ID: 30783800
[TBL] [Abstract][Full Text] [Related]
22. Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial.
Strand V; Kremer JM; Gruben D; Krishnaswami S; Zwillich SH; Wallenstein GV
Arthritis Care Res (Hoboken); 2017 Apr; 69(4):592-598. PubMed ID: 27565000
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular Comorbidities Relate More than Others with Disease Activity in Rheumatoid Arthritis.
Crepaldi G; Scirè CA; Carrara G; Sakellariou G; Caporali R; Hmamouchi I; Dougados M; Montecucco C
PLoS One; 2016; 11(1):e0146991. PubMed ID: 26757209
[TBL] [Abstract][Full Text] [Related]
24. Global assessments of disease activity are age-dependent determinant factors of clinical remission in rheumatoid arthritis.
Ito H; Ogura T; Hirata A; Takenaka S; Mizushina K; Fujisawa Y; Katagiri T; Hayashi N; Kameda H
Semin Arthritis Rheum; 2017 Dec; 47(3):310-314. PubMed ID: 28532573
[TBL] [Abstract][Full Text] [Related]
25. Patient-reported outcomes as predictors of remission in early rheumatoid arthritis patients treated with tight control treat-to-target approach.
Kuusalo L; Puolakka K; Kautiainen H; Karjalainen A; Malmi T; Yli-Kerttula T; Leirisalo-Repo M; Rantalaiho V;
Rheumatol Int; 2017 May; 37(5):825-830. PubMed ID: 28289873
[TBL] [Abstract][Full Text] [Related]
26. Effects of Disease-Worsening Following Withdrawal of Etanercept or Methotrexate on Patient-Reported Outcomes in Patients With Rheumatoid Arthritis: Results From the SEAM-RA Trial.
Curtis JR; Stolshek B; Emery P; Haraoui B; Karis E; Kricorian G; Collier DH; Yen PK; Bykerk VP
J Clin Rheumatol; 2023 Jan; 29(1):16-22. PubMed ID: 36459119
[TBL] [Abstract][Full Text] [Related]
27. Tofacitinib with conventional synthetic disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis: Patient-reported outcomes from a Phase 3 randomized controlled trial.
Li Z; An Y; Su H; Li X; Xu J; Zheng Y; Li G; Kwok K; Wang L; Wu Q
Int J Rheum Dis; 2018 Feb; 21(2):402-414. PubMed ID: 29314645
[TBL] [Abstract][Full Text] [Related]
28. Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study.
Damjanov N; Tlustochowicz M; Aelion J; Greenwald M; Diehl A; Bhattacharya I; Peeva E; Menon S; Gourley I
J Rheumatol; 2016 Dec; 43(12):2094-2100. PubMed ID: 27909139
[TBL] [Abstract][Full Text] [Related]
29. Impact of certolizumab pegol on patient-reported outcomes in rheumatoid arthritis and correlation with clinical measures of disease activity.
Pope J; Bingham CO; Fleischmann RM; Dougados M; Massarotti EM; Wollenhaupt J; Duncan B; Coteur G; Weinblatt ME
Arthritis Res Ther; 2015 Nov; 17():343. PubMed ID: 26614481
[TBL] [Abstract][Full Text] [Related]
30. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity.
Studenic P; Radner H; Smolen JS; Aletaha D
Arthritis Rheum; 2012 Sep; 64(9):2814-23. PubMed ID: 22810704
[TBL] [Abstract][Full Text] [Related]
31. An index of only patient-reported outcome measures, routine assessment of patient index data 3 (RAPID3), in two abatacept clinical trials: similar results to disease activity score (DAS28) and other RAPID indices that include physician-reported measures.
Pincus T; Bergman MJ; Yazici Y; Hines P; Raghupathi K; Maclean R
Rheumatology (Oxford); 2008 Mar; 47(3):345-9. PubMed ID: 18238788
[TBL] [Abstract][Full Text] [Related]
32. Suppressing Inflammation in Rheumatoid Arthritis: Does Patient Global Assessment Blur the Target? A Practice-Based Call for a Paradigm Change.
Ferreira RJO; Duarte C; Ndosi M; de Wit M; Gossec L; da Silva JAP
Arthritis Care Res (Hoboken); 2018 Mar; 70(3):369-378. PubMed ID: 28544615
[TBL] [Abstract][Full Text] [Related]
33. Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis.
Doumen M; De Cock D; Pazmino S; Bertrand D; Joly J; Westhovens R; Verschueren P
Arthritis Res Ther; 2021 Oct; 23(1):269. PubMed ID: 34706771
[TBL] [Abstract][Full Text] [Related]
34. Levofloxacin treatment in patients with rheumatoid arthritis receiving methotrexate.
Ogrendik M
South Med J; 2007 Feb; 100(2):135-9. PubMed ID: 17330681
[TBL] [Abstract][Full Text] [Related]
35. Factors associated with sarcopenia in Japanese patients with rheumatoid arthritis: results from the IORRA cohort study.
Nakayama M; Furuya T; Inoue E; Tanaka E; Ikari K; Yamanaka H; Harigai M
Clin Rheumatol; 2024 Jan; 43(1):521-526. PubMed ID: 37731082
[TBL] [Abstract][Full Text] [Related]
36. Efficacy, safety, pharmacokinetics and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study.
Iwahashi M; Inoue H; Matsubara T; Tanaka T; Amano K; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T
Mod Rheumatol; 2014 Nov; 24(6):885-91. PubMed ID: 24708204
[TBL] [Abstract][Full Text] [Related]
37. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis.
Dervieux T; Furst D; Lein DO; Capps R; Smith K; Walsh M; Kremer J
Arthritis Rheum; 2004 Sep; 50(9):2766-74. PubMed ID: 15457444
[TBL] [Abstract][Full Text] [Related]
38. Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener's).
Tomasson G; Davis JC; Hoffman GS; McCune WJ; Specks U; Spiera R; St Clair EW; Stone JH; Merkel PA
Arthritis Rheumatol; 2014 Feb; 66(2):428-32. PubMed ID: 24504815
[TBL] [Abstract][Full Text] [Related]
39. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs.
Strand V; Kremer J; Wallenstein G; Kanik KS; Connell C; Gruben D; Zwillich SH; Fleischmann R
Arthritis Res Ther; 2015 Nov; 17():307. PubMed ID: 26530039
[TBL] [Abstract][Full Text] [Related]
40. Factors influencing patient-reported outcomes in ANCA-associated vasculitis: correlates of the Patient Global Assessment.
Monti S; Delvino P; Klersy C; Coppa G; Milanesi A; Montecucco C
Semin Arthritis Rheum; 2022 Oct; 56():152048. PubMed ID: 35780724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
